Adagene Inc. has announced that its anti-CTLA-4 therapy, muzastotug (ADG126), developed using the company's proprietary SAFEbody® technology, has received FDA Fast Track Designation for the treatment of microsatellite stable $(MSS)$ colorectal cancer. The company highlighted encouraging responses seen with muzastotug in combination with pembrolizumab, suggesting the potential to improve survival and quality of life for patients. Adagene stated that updated topline Phase 1b/2 clinical data will be shared in the coming months, as the program progresses towards a Phase 3 trial with overall survival as the primary endpoint.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9602765-en) on December 16, 2025, and is solely responsible for the information contained therein.